BNP Paribas Arbitrage SA cut its stake in shares of Natus Medical Inc. (NASDAQ:BABY) by 53.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,766 shares of the company’s stock after selling 5,550 shares during the period. BNP Paribas Arbitrage SA’s holdings in Natus Medical were worth $187,000 as of its most recent filing with the SEC.
Several other hedge funds have also bought and sold shares of the stock. Clinton Group Inc. boosted its stake in Natus Medical by 0.7% in the second quarter. Clinton Group Inc. now owns 8,614 shares of the company’s stock valued at $326,000 after buying an additional 64 shares in the last quarter. PineBridge Investments L.P. boosted its position in shares of Natus Medical by 3.7% in the second quarter. PineBridge Investments L.P. now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 149 shares in the last quarter. Suntrust Banks Inc. boosted its position in shares of Natus Medical by 3.7% in the second quarter. Suntrust Banks Inc. now owns 5,776 shares of the company’s stock valued at $218,000 after buying an additional 204 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Natus Medical by 1.8% in the second quarter. Arizona State Retirement System now owns 17,206 shares of the company’s stock valued at $650,000 after buying an additional 300 shares in the last quarter. Finally, Invictus RG boosted its position in shares of Natus Medical by 8.7% in the second quarter. Invictus RG now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 336 shares in the last quarter. 87.92% of the stock is owned by institutional investors and hedge funds.
Natus Medical Inc. (NASDAQ:BABY) opened at 40.59 on Friday. The stock has a 50 day moving average price of $40.59 and a 200-day moving average price of $36.88. Natus Medical Inc. has a 12-month low of $29.54 and a 12-month high of $51.05. The firm has a market capitalization of $1.32 billion, a PE ratio of 34.99 and a beta of 0.78.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.03. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The business earned $96 million during the quarter, compared to analyst estimates of $92.71 million. During the same period in the prior year, the company posted $0.34 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, equities research analysts forecast that Natus Medical Inc. will post $1.55 EPS for the current year.
BABY has been the subject of several research reports. Zacks Investment Research raised Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Thursday, July 7th. Benchmark Co. initiated coverage on Natus Medical in a report on Tuesday. They set a “buy” rating and a $55.00 price objective for the company. Finally, Raymond James Financial Inc. raised Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price objective for the company in a report on Tuesday, September 13th.
In other Natus Medical news, insider James B. Hawkins acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 28th. The stock was acquired at an average cost of $38.48 per share, with a total value of $384,800.00. Following the acquisition, the insider now directly owns 459,725 shares of the company’s stock, valued at approximately $17,690,218. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.80% of the stock is owned by corporate insiders.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc. (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.